Jama Oncology最新文献

筛选
英文 中文
Error in Author Affiliation. 作者归属错误。
IF 20.1 1区 医学
Jama Oncology Pub Date : 2025-09-01 DOI: 10.1001/jamaoncol.2025.3830
{"title":"Error in Author Affiliation.","authors":"","doi":"10.1001/jamaoncol.2025.3830","DOIUrl":"10.1001/jamaoncol.2025.3830","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":"11 9","pages":"1099"},"PeriodicalIF":20.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12447252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145081971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erroneous References. 错误的引用。
IF 20.1 1区 医学
Jama Oncology Pub Date : 2025-09-01 DOI: 10.1001/jamaoncol.2025.3587
{"title":"Erroneous References.","authors":"","doi":"10.1001/jamaoncol.2025.3587","DOIUrl":"10.1001/jamaoncol.2025.3587","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1099"},"PeriodicalIF":20.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12340676/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Concerns About Conclusions of the POLAR Trial-Reply. 对POLAR试验结论的关注-答复。
IF 20.1 1区 医学
Jama Oncology Pub Date : 2025-09-01 DOI: 10.1001/jamaoncol.2025.2358
Laura L Michel, Jana Müller, Markus Weiler
{"title":"Concerns About Conclusions of the POLAR Trial-Reply.","authors":"Laura L Michel, Jana Müller, Markus Weiler","doi":"10.1001/jamaoncol.2025.2358","DOIUrl":"10.1001/jamaoncol.2025.2358","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1098"},"PeriodicalIF":20.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Limitations in Adjuvant Chemoradiotherapy Study-Reply. 辅助放化疗的局限性研究——回复。
IF 20.1 1区 医学
Jama Oncology Pub Date : 2025-09-01 DOI: 10.1001/jamaoncol.2025.2114
Nuria Agustí, David Viveros-Carreño, J Alejandro Rauh-Hain
{"title":"Limitations in Adjuvant Chemoradiotherapy Study-Reply.","authors":"Nuria Agustí, David Viveros-Carreño, J Alejandro Rauh-Hain","doi":"10.1001/jamaoncol.2025.2114","DOIUrl":"10.1001/jamaoncol.2025.2114","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1094"},"PeriodicalIF":20.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Managing Agitated Delirium at the End of Life-A Knockout Trial. 生命末期躁动性谵妄的治疗——一项令人震惊的试验。
IF 20.1 1区 医学
Jama Oncology Pub Date : 2025-09-01 DOI: 10.1001/jamaoncol.2025.2175
Justin J Sanders, James Downar
{"title":"Managing Agitated Delirium at the End of Life-A Knockout Trial.","authors":"Justin J Sanders, James Downar","doi":"10.1001/jamaoncol.2025.2175","DOIUrl":"10.1001/jamaoncol.2025.2175","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1043-1044"},"PeriodicalIF":20.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Error in Figure 1. 图1中的错误。
IF 20.1 1区 医学
Jama Oncology Pub Date : 2025-09-01 DOI: 10.1001/jamaoncol.2025.3795
{"title":"Error in Figure 1.","authors":"","doi":"10.1001/jamaoncol.2025.3795","DOIUrl":"10.1001/jamaoncol.2025.3795","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":"11 9","pages":"1099"},"PeriodicalIF":20.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12447230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145081962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Limitations in Adjuvant Chemoradiotherapy Study. 辅助放化疗研究的局限性。
IF 20.1 1区 医学
Jama Oncology Pub Date : 2025-09-01 DOI: 10.1001/jamaoncol.2025.2111
Sümerya Duru Birgi, Salih Taskin, Yüksel Ürün
{"title":"Limitations in Adjuvant Chemoradiotherapy Study.","authors":"Sümerya Duru Birgi, Salih Taskin, Yüksel Ürün","doi":"10.1001/jamaoncol.2025.2111","DOIUrl":"10.1001/jamaoncol.2025.2111","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1093"},"PeriodicalIF":20.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Who Needs Axillary Dissection After Neoadjuvant Therapy? 新辅助治疗后哪些人需要腋窝清扫?
IF 20.1 1区 医学
Jama Oncology Pub Date : 2025-08-28 DOI: 10.1001/jamaoncol.2025.2712
Abram Recht
{"title":"Who Needs Axillary Dissection After Neoadjuvant Therapy?","authors":"Abram Recht","doi":"10.1001/jamaoncol.2025.2712","DOIUrl":"https://doi.org/10.1001/jamaoncol.2025.2712","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":20.1,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144975132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumor-Infiltrating Lymphocytes-An Area of Standardization. 肿瘤浸润性淋巴细胞-一个标准化的领域。
IF 20.1 1区 医学
Jama Oncology Pub Date : 2025-08-01 DOI: 10.1001/jamaoncol.2025.1849
Elif Sertesen Camoz, Ilknur Deliktas Onur, Fatih Yildiz
{"title":"Tumor-Infiltrating Lymphocytes-An Area of Standardization.","authors":"Elif Sertesen Camoz, Ilknur Deliktas Onur, Fatih Yildiz","doi":"10.1001/jamaoncol.2025.1849","DOIUrl":"10.1001/jamaoncol.2025.1849","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"921"},"PeriodicalIF":20.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Effectiveness Associated With Fecal Immunochemical Testing for Early-Age Screening. 粪便免疫化学检测在早期筛查中的长期有效性。
IF 20.1 1区 医学
Jama Oncology Pub Date : 2025-08-01 DOI: 10.1001/jamaoncol.2025.1433
Han-Mo Chiu, Sam Li-Sheng Chen, Chiu-Wen Su, Amy Ming-Fang Yen, Wen-Feng Hsu, Chen-Yang Hsu, Ting-Yu Lin, Yi-Chia Lee, Ming-Shiang Wu, Tony Hsiu-Hsi Chen
{"title":"Long-Term Effectiveness Associated With Fecal Immunochemical Testing for Early-Age Screening.","authors":"Han-Mo Chiu, Sam Li-Sheng Chen, Chiu-Wen Su, Amy Ming-Fang Yen, Wen-Feng Hsu, Chen-Yang Hsu, Ting-Yu Lin, Yi-Chia Lee, Ming-Shiang Wu, Tony Hsiu-Hsi Chen","doi":"10.1001/jamaoncol.2025.1433","DOIUrl":"10.1001/jamaoncol.2025.1433","url":null,"abstract":"<p><strong>Importance: </strong>The rising incidence of young-onset colorectal cancer (CRC) has prompted health policymakers to consider lowering the recommended starting age for screening. However, population-based evidence supporting the long-term effectiveness of early-age screening remains limited.</p><p><strong>Objective: </strong>To evaluate whether initiating fecal immunochemical test (FIT) screening at ages 40 to 49 years, rather than at the currently recommended age of 50 years, reduces CRC incidence and mortality.</p><p><strong>Design, setting, and participants: </strong>This study analyzed a community-based screening cohort of Taiwanese residents aged 40 to 49 years, categorized into 4 subcohorts based on participation in early screening (age 40 to 49 years) and continuation of nationwide regular screening (50 years and older). The cohort was followed up until 2019 to compare CRC incidence and mortality across subcohorts. To mitigate self-selection bias, a delayed screening design and efficient propensity score matching was used, restricting analyses to participants attending regular screening. To validate the findings, an extended nonadherence adjustment was applied to all 4 subcohorts. Data were collected from January 2001 to December 2019, and data were analyzed from January 2021 to December 2024.</p><p><strong>Exposures: </strong>Biennial FIT screening was initiated for the early screening group at ages 40 to 49 years and for the regular screening group at age 50 years, with follow-up continuing under Taiwan's national screening program.</p><p><strong>Main outcomes and measures: </strong>Primary outcomes were CRC incidence and mortality rates, reported as cases per 100 000 person-years, with adjusted relative risks (aRRs) comparing early vs regular screening groups.</p><p><strong>Results: </strong>Of 263 125 included participants, 146 796 (55.8%) were female. A total of 39 315 participated in early and regular screening, and 223 810 participated in regular screening only. The early screening group exhibited lower CRC incidence (26.1 [95% CI, 22.3-29.9] vs 42.6 [95% CI, 40.5-44.7] per 100 000 person-years) and mortality (3.2 [95% CI, 1.9-4.6] vs 7.4 [95% CI, 6.5-8.2] per 100 000 person-years). In propensity score-matched analyses, early screening significantly reduced CRC incidence (aRR, 0.79; 95% CI, 0.67-0.94) and mortality (aRR, 0.61; 95% CI, 0.38-0.98). Findings were consistent in the extended nonadherence adjustment model, showing a 25% reduction in incidence (aRR, 0.75; 95% CI, 0.72-0.77) and a 34% reduction in mortality (aRR, 0.66; 95% CI, 0.62-0.71).</p><p><strong>Conclusions and relevance: </strong>This study found that initiating FIT screening at age 40 to 49 years was associated with further reduction in CRC mortality and incidence compared with starting screening at age 50 years. These results provide strong empirical support for lowering the CRC screening age, with substantial public health implications.</p>","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"846-854"},"PeriodicalIF":20.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12163714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信